TGFB1 and focal segmental glomerulosclerosis: A subsequent phase II multicenter, double-blind, placebo-controlled randomized study of another neutralizing antibody (fresolimumab) against all three TGFβ isoforms was evaluated in patients with primary focal segmental glomerulosclerosis (FSGS).